The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts

Dušan Milanović1,4*, Friederike Braun2, Wolfgang Weber2, Anca Ligia Grosu1, Martin Behe3 and Gabriele Niedermann1

Abstract

**Background:** One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents (VDA) that cause disruption of established tumor vessels and subsequent tumor hemorrhagic necrosis. Its selective antivascular effect is mediated by intratumoral induction of several cytokines including tumor necrosis factor-α (TNF-α), granulocyte-colony-stimulating factor (G-CSF), interleukin 6 (IL-6) and macrophage inflammatory protein 1α (MIP-1α). Preclinical studies have demonstrated that ASA404 acts synergistically with taxanes. In this study, we investigated if treatment of mice bearing U251 human glioblastoma xenografts with ASA404 and taxol may be synergistic. Therapy response was evaluated by measuring changes in tumor size and metabolic activity using 18F-FDG PET (Fluorodeoxyglucose - positron emission tomography) imaging.

**Methods:** U251 cells were inoculated s.c. in the right hind limb of NMRI-Foxn1nu athymic female nude mice. Animals were randomly assigned into 4 groups (7–9 animals/group) for treatment: control, taxol, ASA404, and ASA404 plus taxol. The animals received either a single dose of taxol (10 mg/kg), ASA404 (27.5 mg/kg), or taxol (10 mg/kg) plus ASA404 (27.5 mg/kg) administered i.p.; ASA404 was administered 24 h after the treatment with taxol. 4 and 24 h after treatment with ASA404 (28 and 48 h hours after treatment with taxol) 18F-FDG PET scans were performed.

**Results:** The treatment with taxol did not affect the tumor growth in comparison to untreated controls. The treatment of animals with single dose ASA404 alone or in combination with taxol caused a significant delay in tumor growth. The combined treatment did not decrease the growth of the xenografts significantly more than ASA404 alone, but early changes in tumor 18F-FDG uptake preceded subsequent growth inhibition. The tumor weights, which were determined at the end of treatment, were lower in case of combined treatment.

**Conclusions:** The treatment with ASA404 alone or in combination with taxol showed antitumoral effects in our glioblastoma model probably through destruction of blood vessels. The implications for the anticancer effect of this compound warrant further preclinical studies. 18F-FDG PET appears to be a promising tool to monitor treatment with ASA404 early in the course of therapy.

* Correspondence: dušan.milanovic@uniklinik-freiburg.de
1 Department of Radiation Oncology, University Hospital Freiburg, Freiburg 79106, Germany
4 University Hospital Freiburg, Department of Radiation Oncology, Robert Koch Strasse 3, Freiburg D-79106, Germany

© 2012 Milanović et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Glioblastoma multiforme (GBM) is the most common brain tumour of astrocytic origin [1]. Despite the use of multimodal therapy (surgery and radiochemotherapy with Temozolomide) the prognosis of patients with this highly aggressive neoplastic disease remains poor with a median survival time of 14.6 months [2]. One of the most important biological characteristics of GBM is high vascular density. Thus targeting the vasculature in this tumour could be an attractive therapeutic strategy [3]. Bevacizumab is a monoclonal antibody against VEGF (Vascular Endothelial Growth Factor), which is one of key proteins stimulating the growth of new blood vessels (angiogenesis) in glioblastomas [4]. This drug was granted accelerated approval by the US Food and Drug Administration (FDA) as a single agent in recurrent GBM [5].

ASA404 was kindly provided by Novartis Pharma AG Basel, Switzerland. ASA404 powder was dissolved in phosphate buffered saline directly prior to administration. Stock solution of taxol (Sigma-Aldrich, Taukirchen, Germany) was prepared using dimethylsulfoxide (DMSO) as the vehicle and appropriately diluted in saline before treatments. Animals with 10 days-old xenografts were randomly assigned in 4 groups (7–9 animals/group) for treatment: control, taxol, ASA404 and ASA404 plus taxol. The animals received either a single dose of taxol (10 mg/kg), ASA404 (27.5 mg/kg), or taxol (10 mg/kg) plus ASA404 (27.5 mg/kg) administered i.p.; ASA404 was administrated 24 h after the treatment with taxol. Animals in the control group were treated with DMSO i.p. Animal weight was measured daily. In order to determine tumor volume by external caliper, the greatest longitudinal diameter (length) and the greatest transverse diameter (width) were determined. Tumor volume based on caliper measurements was calculated by the modified ellipsoidal formula:

\[
\text{Tumor volume} = \frac{1}{2} \times (\text{length} \times \text{width}^2)
\]

15 days after initiation of treatment animals were sacrificed following the IACUC guidelines. Xenografts were surgically excised and their weights were measured.

PET scanning
PET imaging was performed with a microPET focus 120 small animal PET scanner (Concorde, Knoxville, TN). After 4–8 h of fasting, 7.4 MBq \(^{18}\)F-FDG was injected via a lateral tail vein. For \(^{18}\)F-FDG injection and imaging the mice were anesthesised with 1.5–2% Isoflurane. PET imaging was started 60 min after injection. Image acquisition time was 10 min. Images were corrected for deadtime and randoms and reconstructed by the routine OSEM2D (2-Dimensional Reconstruction) algorithm provided by the manufacturer. Image counts per pixel per second were calibrated to activity concentrations
(Bq/ml) by measuring a 3.5-cm cylinder phantom filled with a known concentration of $^{18}$F-FDG [16,17]. The resolution of the reconstructed images ranged between 1.5-2 mm depending on the distance from the center of the field of view [18]. $^{18}$F-FDG uptake by the tumor xenografts, brain and liver was quantified by maximum standardized uptake values (SUVs) normalized to the weight of the animals. Quantitative analysis was performed with the Amide software [19]. In order to identify the maximum tumor $^{18}$F-FDG uptake large ellipsoid regions of interests were drawn around the whole tumor area and organ, respectively. The voxel with the maximum $^{18}$F-FDG uptake was then identified automatically by the Amide software.

**Statistical analysis**

Mann-Whitney $U$ test was used to compare quantification data. Statistical analysis was conducted with Statistical Package for Social Sciences software (SPSS Inc.). We used a 2-sided significance level of 0.05 for all statistical analyses.

**Results**

**Tolerability of treatment**

The treatment with taxol as a sole compound was well tolerated. No side effects were observed. In animals, which were treated with ASA404 alone or in combination with taxol, slight diarrhea and significant weight loss were observed after 1 day of treatment with ASA404 with full recovery by 3 days [Figure 1]. Weights of animals remained relatively constant for the rest of the experimental period.

**Activity of ASA404 and taxol on the growth and weight of U251 human glioblastoma xenografts**

The treatment with taxol did not affect the tumor growth in comparison to untreated controls. The treatment of animals with single dose ASA404 alone or in combination with taxol caused a significant decrease in tumor volume [Figure 2A]. At the completion of the study, weights of the excised tumors were: control = 764 ± 168 mg, taxol = 651 ± 148 mg, ASA404 = 283 ± 127 mg, ASA404 + taxol = 180 ± 56 mg. ASA404 as a sole agent caused a significant decrease in tumor weight. In case of combined treatment, statistically significant lower tumor weight was observed compared to treatment with ASA404 as a single agent ($p = 0.0198$) [Figure 2B]. Already 8 h after treatment, xenografts in animals treated with ASA404 alone [Figure 3C] or in combination with taxol [Figure 3D] remarkably changed color. This change was not observed in untreated animals [Figure 3A] or in animals which were treated only with taxol [Figure 3B].

**PET**

The treatment with taxol did not affect the $^{18}$F-FDG uptake in comparison to untreated controls. However, the treatment of animals with ASA404 caused a rapid and marked decrease in tumor $^{18}$F-FDG uptake already 4 h after treatment with ASA404 ($p = 0.0495$ - three mice in each group). There was a similar decrease in $^{18}$F-FDG uptake at 24 h after treatment with ASA404 ($p = 0.0455$). The combined therapy with ASA404 and taxol showed significant reduction of the $^{18}$F-FDG uptake, too, comparable to the one observed with ASA404 alone. Between 1–12 h after this investigation, several mice treated with ASA404 alone or in combination with taxol died. However, no significant change of $^{18}$F-FDG uptake was observed in the brain [Figure 4B] and liver [Figure 4C] in ASA404 treated animals in comparison to untreated control. No mice died in groups which were not used for PET studies and which were treated with the same drugs respectively, but a transient significant weight loss was observed in all ASA404 treated animals.

**Discussion**

Despite intensive research and development of new targeted therapies and radiotherapeutic techniques, prognosis for patients with GBM remains poor indicating the need for new therapeutic approaches. Because of high vascular density of these tumors development of therapies selectively targeting the tumor vasculature may be meaningful. The aim of this study was to identify if the combined treatment with ASA404 and taxol shows synergistic effects in mice bearing U251 human glioblastoma.
xenografts and if non-invasive $^{18}$F-FDG PET imaging could be used to monitor tumor response early in the course of therapy. Tumors of animals which were treated with ASA404 as a sole agent or in combination with taxol showed significant growth delay in comparison with control or animals which were treated only with taxol. Combined treatment with taxol and ASA404 had a similar effect on tumor growth as ASA404 alone. At the completion of the study, there was only slight but statically significant difference in tumor weight for animals treated with the drug combination as compared to animals receiving ASA404 alone. This difference in statistical significance between the two parameters which were analysed (tumor volume and tumor weight) can be explained by the use of a formula in which one important parameter of the tumor growth – tumor depth, was not considered. The tumor weights were determined only at the end of treatment and in this may represent a more precise parameter to determine an effect of the therapy. On the other hand, the differences among treatment groups were very small. Thus, based on these data, it is difficult to conclude if combined treatment was synergistic. GBM represents one of the most vascularized tumors [20]. Antiangiogenic agents, such as bevacizumab, which is approved for treatment of recurrent GBM patients who have failed previous temozolomide and radiation therapy, inhibit new blood vessel formation from preexisting vasculature [5]. Furthermore, antiangiogenic agents can normalize the tumor vasculature and decrease interstitial fluid pressure, providing an improved drug delivery [21]. In contrary to antiangiogenic agents, VDAs such as ASA404, have a selective affinity to existing tumor blood vessels inducing their collapse which impairs blood flow, oxygen supply and consequently causes necrosis in tumor tissue [22].

The synergistic mechanism between ASA404 and taxol seems not to involve potentiation of the vascular disrupting activity of ASA404 or a pharmacokinetic interaction between these two drugs. The synergism might be explained by complementary action against the different subregions of the tumor; ASA404 is more active in the poorly vascularized regions while taxol is active in the well vascularized regions [12]. In addition to its direct cytotoxic effects, taxol can induce the expression of proinflammatory cytokines, such as TNF-$\alpha$ and IL-6 [23] which are important mediators of ASA404 activity [7,8]. Thus, taxol and ASA404 can induce of same cytokines which are responsible for tumor vascular disruption.

It has been reported that chemotherapy drugs should be administered before, or shortly after ASA404 in order to avoid compromised delivery. When taxol was administered 4 h after ASA404, considerable loss of antitumor activity has been observed apparently caused by decreased blood flow which may inhibit taxol distribution in tumor tissue [12].

As opposed to conventional antineoplastic agents, effects of VDAs such as ASA404 do not result in dramatic changes in tumor volume [22,24]. This indicates that new approaches are necessary to monitor tumor response to VDAs. We found that $^{18}$F-FDG uptake decreased rapidly after administration of ASA404. This result is consistent with findings that highest increase of intratumoral TNF-$\alpha$ activity is also observed 4 h after treatment with ASA404 [25]. We suppose that the marked reduction in tumor $^{18}$F-FDG uptake is at least

---

**Figure 2** The effect of taxol and ASA404 as sole agents or in combination on xenograft volume at different time points [A] and weight [B] at the end of treatment. The treatment of animals with taxol did not affect xenograft growth in comparison to untreated controls. Treatment with ASA404 alone or in combination with taxol caused significant growth delay of tumors in comparison to control or animals which were treated with taxol as a sole compound. There was not significant difference in tumor growth delay between animals which were treated with ASA404 alone or in combination with taxol. On the end of the treatment, the tumor weight of animals treated with the ASA404 and taxol combination were significantly lower than from animals which were treated only with ASA 404.

---
partly a reflection of tumor cell death. Moreover, it seems likely that a significant fraction of tumor cells will become necrotic, if perfusion is decreased to such an extent that 18 F-FDG uptake significantly decreases. Preclinical studies in different tumor models have demonstrated that ASA404 directly disrupts the tumor vasculature by selectively inducing apoptosis in tumor-vascular endothelial cells [26,27]. On the other hand, the reason why several of the mice who underwent PET imaging died within several hours after the PET scan is not entirely clear. Because of ASA404 antivascular properties, we presumed that bleeding might cause this effect. Surprisingly, mouse dissection did not show any bleeding source. There is only one report on the use of small animal PET as a biomarker for response to ASA404 [28]. In this case, 18 F-fluromisonidazole (FMISO) PET imaging was conducted and no side effects have been reported. Before application of the 18 F-FMISO tracer, the animals do not have to fasten.

It has been shown that the administration of TNF-α, which is an important mediator of ASA404 antitumoral action, decreases serum glucose levels in mice [29]. For improving tumor visualization, mice have to fasten a 18 F-FDG injection uptake period [30]. We speculate that the combination of ASA404 mediated TNF-α secretion with starving and anesthesia for PET investigation may have caused death of mice.

It has been reported that treatment of nude mice bearing U87 and GL261 orthotopically grown human glioblastoma cells with ASA404 caused statistically significant increase in median survival compared to untreated controls [31]. Measurement with contrast-enhanced magnetic resonance imaging (MRI) and diffusion-weighted MRI which were used to determine tumor blood flow 24 h after treatment with ASA404 clearly demonstrated extravasation and accumulation of the contrast agent in the tumor indicating treatment-induced vascular disruption. Similar effects were observed in fibrosarcoma (MCA205) ectopic and orthotopic tumor models. Remarkably, 3 h after treatment with ASA404 ectopic tumors showed 6-fold greater induction of TNF-α compared to orthotopic tumors [32]. In our glioblastoma U251 model, the rapid mode of action of ASA404 became also apparent by the changes in tumor color 8 h post injection which indicates hemorrhagic necrosis.

It is believed that VDAs are more effective against vessels inside of the tumor. In the periphery of the tumor a

Figure 3 Color change of xenografts 32 h after the treatment with taxol (B), 8 h after the treatment with ASA404 (C) or 32 h after the treatment with taxol plus a ASA404 during the last 8 h (D). Xenograft (A) represents an untreated control. Treatment with ASA404 as a sole agent or in combination with taxol most probably caused change of permeability and selective disruption of blood vessels within tumors followed by hemorrhagic necrosis.
characteristic rim of cells will remain viable after treat-
ment [33,34].

In our experiments, tumors of animals which were trea-
ted with ASA404 as a sole agent or in combination with
taxol, showed significant growth delay in comparison with
control or animals which were treated only with taxol. In
both group of ASA404-treated animals, tumor start to re-
growth between 11 und 13 days after treatment.

Despite the significant smaller tumors, 20 days after
treatment, histopathologic examination revealed that all
treated tumors maintained the characteristic growth of
glioblastoma without any difference between the differ-
ent treatment groups (data not shown). No significant
increase in the level of cell death occurred in tumors of
animals treated with ASA404 indicating that surviving
tumor cells were able to proliferate causing tumor re-
growth. In the Colon 38 adenocarcinoma tumor model
[35], the antitumor effect of ASA404 was schedule-
dependent. 100% of the tumors regressed, when the
mice were treated with loading (25 mg/kg) and two sup-
plementary (5 mg/kg) doses after 4 and 8 h while in
mice treated with a single dose of ASA404 (25 mg/kg)
40% of tumors regressed. We supose that with a pro-
longed therapy better antitumoral responses might be
achieved. The first clinical data obtained from I/II phase
clinical trials evaluating ASA404 in combination with
taxol and carboplatin in patients with untreated
advanced non-small lung cancer were promising [36]
but in one large, randomized phase III placebo controled
trial, these results were not confirmed [37].

Conclusions
We conclude that treatment with ASA404 showed sig-
ificant antitumoral effects in our glioblastoma model.
This warrants further preclinical studies of ASA404 in other glioblastoma models and in combination with conventional antineoplastic drugs such as temozolomide and carmustine standardly used in the treatment of glioblastoma. Further understanding of the mechanisms of VDAs for treatment optimization is necessary. If the toxicity associated with the \(^{18}\)F-FDG PET examination would not occur in tumor patients, \(^{18}\)F-FDG PET could be a promising tool to monitor the drug effects in the clinic early in the course of therapy.

**Competing interests**

Authors declare that there are no financial interests in relation to the work described.

**Authors’ contributions**

DM was the principal investigator of the study and largely wrote the manuscript. FB and MB designed and conducted small animal PET experiments. WAV analysed PET experiments and participated in writing the manuscript. ALG provided clinical information and participated in the design of the study. GN supervised the research, analysed and interpreted data, and participated in writing the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

The work was supported by a grant from Novartis Pharma GmbH, Freiburg, Freiburg 79106, Germany. The sponsor had no involvement in the study design, data analysis and interpretation or decision to publish.

**Author details**

1. Department of Radiation Oncology, University Hospital Freiburg, Freiburg 79106, Germany. 2. Department of Nuclear Medicine, University Hospital Freiburg, Freiburg 79106, Germany. 3. Paul Scherer Institut, Center for Radiopharmaceutical Sciences, Wolfgang-Pauli Strasse 10, Zurich CH-8093, Switzerland. 4. University Hospital Freiburg, Department of Radiation Oncology, Robert Koch Strasse 3, Freiburg D-79106, Germany.

**Received**: 17 January 2012 **Accepted**: 5 June 2012

**References**

1. DeAngelis LM: Brain tumors. N Engl J Med 2001, 344:114–123.
2. Mirmanoff RD, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006, 24:2563–2569.
3. Wong ET, Brem S: Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008, 6:515–522.
4. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845–848.
5. Cohen MH, Shen YL, Keegan P, Pazdur R: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14:1131–1138.
6. Rehman F, Rustin G: ASA404: update on drug development. Expert Opin Investig Drugs 2008, 17:1547–1551.
7. Browne WL, Wilson WR, Baguley BC, Ching LM: Suppression of serum tumour necrosis factor- \(\beta\) by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumor activity of 5,6-dimethylxanthene-4-acetic acid. Anticancer Res 1998, 18:4409–4413.
8. Wang LC, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen CJ, Angel CE, Dunbar PR, Ching LM: Neutrophil influx and chemokine production during the early phases of the antitumour response to the vascular disrupting agent DMXAA (ASA404). Neoplasia 2009, 11:793–803.
9. Baguley BC, Zhuang L, Kestel P: Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthene-4-acetic acid, vinblastine, and colchicines: relation to vascular effects. Oncol Res 1997, 9:55–60.
10. Thomsen L, Baguley BC, Wilson WR: Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumor cell killing by flavone-8-acetic acid and 5,6-dimethylxanthene-4-acetic acid. Cancer Chemother Pharmacol 1992, 3:151–155.
11. Cao Z, Baguley BC, Ching LM: Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthene-4-acetic acid (DMXAA). Cancer Res 2001, 61:1517–1521.
12. Sim BG, Lee AE, Shahal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR: Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthene-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003, 51(1):43–52.
13. Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978, 62:1219–1222.
14. Pasquier E, Honore S, Prouzy B, Jordan MA, Lehmann M, Brillard C, Braguer D: Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005, 65:2433–2440.
15. Dorsev JP, Mitaz A, Tian X, Dowlings ML, Platas MJP, Dicker DT, Xiao GD, Ellis WS: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther 2009, 8:3285–3295.
16. Wei LH, Su H, Hildebrandt Ud, Phelps ME, Czernin J, Weber WA: Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 2008, 14:3416–3426.
17. Su H, Bodenstein C, Dumont RA, Seibellie Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W: Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006, 12:5659–5667.
18. Kim JS, Lee JS, Im KC, Kim SJ, Kim SY, Lee DS, Moon DH: Performance measurement of the microPET focus 120 scanner. J Nucl Med 2007, 48:1527–1535.
19. Loening AM, Gambhir SS: AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003, 2:131–137.
20. Jain RK, di Tomaso E, Duda DG, Loeffer JS, Sorensen AG, Batchelor TT: Angiogenesis in brain tumors. Nat Rev Neurosci 2007, 8:650–662.
21. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58–62.
22. Tozer GM, Kanthou C, Baguley BC: Accessing tumour blood vessels, Nat Rev Cancer 2005, 5:423–435.
23. Fitzpatrick FA, Wheeler R: The immunopharmacology of paclitaxel (taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 2003, 3:1699–1714.
24. Siemann DW, Mercer E, Lepler S, Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy, Int J Cancer 2002, 99:1–4.
25. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM: Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthene-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999, 59:633–638.
26. Ching LM, Zwan S, Baguley BC: Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004, 90:906–910.
27. Ching L-M, Cao Z, Kieda C, Zwan S, Jameson MB, Baguley BC: Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthene-4-acetic acid. Br J Cancer 2002, 86:1937–1942.
28. Oehler C, DoNofrrecha JA, Russell J, Zanuncio P, Lorenzen S, Ling CC, Carlin S: 18 F-Fluoromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthene-4-acetic acid in colorectal xenograft tumors. J Nucl Med 2011, 52:437–444.
29. Benigni F, Atsumi T, Calandra T, Metz C, Echtenacher B, Peng T, Bucala R: The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 2000, 106:1291–1300.
30. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpem BS, Stout D, Phelps ME, Weber WA: Impact of animal handling on the results of 18 F-FDG PET studies in mice. *J Nucl Med* 2006, 47:999–1006.

31. Seshadri M, Ciesielski MJ: MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. *J Cereb Blood Flow Metab* 2009, 29:1373–1382.

32. Seshadri M, Bellnier DA, Cheney RT: Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors. *Int J Radiat Oncol Biol Phys* 2008, 72:1198–1207.

33. Baguley BC: Antivascular therapy of cancer: DMXAA. *Lancet Oncol* 2003, 4:141–148.

34. Kelland LR: Targeting established tumor vasculature: a novel approach to cancer treatment. *Carr Cancer Ther Rev* 2005, 1:1–9.

35. Zhao L, Ching LM, Kestell P, Baguley BC: Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. *Clin Cancer Res* 2003, 9:6545–6552.

36. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E: Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. *Br J Cancer* 2008, 99:2006–2012.

37. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Loosnay C, Reck M, Heo DS, Fan X, Fandi A, Scaglotti G: Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. *J Clin Oncol* 2011, 29:2965–2971.

Cite this article as: Milanović et al.: The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts. *BMC Cancer* 2012 12:242.

doi:10.1186/1471-2407-12-242

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit